

RESTRICTED BENEFIT CRITERIA - TUDORZA®

PROVINCE/PROGRAM	INDICATION	CRITERIA
British Columbia SA	COPD	COPD that failed both Spiriva® Respimat® and Incruse®
New Brunswick SA	COPD	Moderate to severe symptomatic COPD Exacerbating COPD As part of an open triple therapy in COPD uncontrolled on LAMA/LABA or ICS/LABA
Newfoundland and Labrador SA	COPD	Moderate to severe symptomatic COPD Exacerbating COPD As part of an open triple therapy in COPD uncontrolled on LAMA/LABA
	ACO	As part of an open triple therapy in patients with an asthma/COPD overlap
Nova Scotia EDS	COPD	Moderate to severe symptomatic COPD Exacerbating COPD As part of an open triple therapy in COPD uncontrolled on LAMA/LABA or ICS/LABA
Prince Edward Island SA	COPD	Moderate to severe symptomatic COPD Exacerbating COPD
Saskatchewan EDS	COPD	COPD not otherwise specified
Yukon EDS	COPD	COPD that failed all other LAMA

ACO: asthma COPD overlap, COPD: chronic obstructive pulmonary disease, EDS: Exception Drug Status, ICS: inhaled corticosteroids, LABA: long-acting beta-agonist, LAMA: long-acting muscarinic antagonist, SA: Special Authorization, SABA: short-acting beta-agonist